APA

Varewijck A. J., Janssen J. A. M. J. L., Vähätalo M., Hofland L. J., Lamberts S. W. J. & Yki-Järvinen H. (20120806). Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. : Diabetologia.

Chicago

Varewijck A J, Janssen J A M J L, Vähätalo M, Hofland L J, Lamberts S W J and Yki-Järvinen H. 20120806. Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. : Diabetologia.

Harvard

Varewijck A. J., Janssen J. A. M. J. L., Vähätalo M., Hofland L. J., Lamberts S. W. J. and Yki-Järvinen H. (20120806). Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. : Diabetologia.

MLA

Varewijck A J, Janssen J A M J L, Vähätalo M, Hofland L J, Lamberts S W J and Yki-Järvinen H. Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. : Diabetologia. 20120806.